Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
MPS Pharmaa Ltd (531686)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531686 NSE: Pharmaceuticals & Drugs | Small Cap | MPS Pharmaa Share Price
₹2.08 0.00 (0.00%)
As on 21-Sep'26 16:59
MPS Pharmaa Ltd (531686)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531686 NSE: Pharmaceuticals & Drugs | Small Cap | MPS Pharmaa Share Price
₹2.08 0.00 (0.00%)
As on 21-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹4 Cr.
Current Price
₹2.1
52-Week Low / High
₹2 / 2
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.8
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
35.89%
Pledged shares (%) of Promoter's holding (%)
16.04%
Reserves
-
Equity
₹19.1 Cr.
Face Value
₹10
All Time Low / High
₹0.32 / 53.25
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is MPS Pharmaa Ltd a good quality company?
MPS Pharmaa Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does MPS Pharmaa Ltd performance compare with that of its Peers?
Revenue growth of MPS Pharmaa Ltd vs industry peers?
MPS Pharmaa Ltd revenue CAGR is %, compared to the industry median CAGR of 0.71%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of MPS Pharmaa Ltd?
Promoters hold 35.89% of the MPS Pharmaa Ltd, with 16.04% of their stake pledged, indicating high pledge risk.
Stock return of MPS Pharmaa Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -8.7% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
MPS Pharmaa Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -4.2% | -33.9% | -5.9% | -7.8% | -8.1% | -36.9% | -9.6% | -11.2% | -9.1% | -9.7% | - |
| Value Creation Index ⓘ | -1.3 | -3.4 | -1.4 | -1.6 | -1.6 | -3.6 | -1.7 | -1.8 | -1.7 | -1.7 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 1.4 | 2.8 | 4.1 | 0.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sales YoY Gr. | - | 110.4% | 44% | -79.7% | -100% | NA | NA | -100% | NA | NA | - |
| Adj EPS ⓘ | -0.6 | -3.9 | -0.5 | -0.7 | -0.6 | -2.4 | -0.1 | -0.6 | -0.4 | -0.5 | -0.5 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 9.9 | 6.1 | 5.6 | 5 | 4.4 | 2.1 | 2 | 1.5 | 1 | 0.6 | -0.1 |
| Adj Net Profit ⓘ | -1.2 | -7.4 | -0.9 | -1.3 | -1.2 | -4.5 | -0.1 | -1.1 | -0.8 | -0.9 | -1 |
| Cash Flow from Ops. ⓘ | 1.3 | 0.4 | -0.3 | 0.6 | -0.5 | -0.9 | -4.3 | -0.9 | -0.6 | -0.6 | - |
| Debt/CF from Ops. ⓘ | 5.3 | 17.9 | -19.5 | 10.5 | -12.8 | -6.1 | -1.3 | -7.8 | -11.5 | -13.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -100% | NA | -100% | NA | ||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||
| BVPSⓘ | -27.2% | -33.5% | -34.2% | -44.7% | ||||
| Share Price | -8.7% | 11.4% | -6.4% | 4.5% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -6.2 | -48.3 | -7.7 | -12.3 | -13 | -73.7 | -3.6 | -31.8 | -34.9 | -58.9 | -225 |
| Op. Profit Mgn % ⓘ | -36.4 | -242 | -12.8 | -86.8 | -15362.1 | 0 | -2079.4 | 0 | 0 | 0 | NAN |
| Net Profit Mgn % ⓘ | -87.9 | -259.8 | -21.1 | -150.5 | -26692.7 | 0 | -437.3 | 0 | 0 | 0 | -INF |
| Debt to Equity ⓘ | 0.4 | 0.6 | 0.6 | 0.7 | 0.8 | 1.4 | 1.5 | 2.4 | 3.7 | 6.9 | - |
| Working Cap Days ⓘ | 4,113 | 1,300 | 621 | 2,611 | 4,39,267 | 0 | 23,660 | 0 | 0 | 0 | 0 |
| Cash Conv. Cycle ⓘ | 3,209 | 1,017 | 413 | 1,651 | 2,62,890 | 0 | 9,803 | 0 | 0 | 0 | 0 |
Valuation of MPS Pharmaa - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
MPS Pharmaa Ltd FAQs
The current trading price of MPS Pharmaa on 21-Sep-2026 16:59 is ₹2.08.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Sep-2026 the market cap of MPS Pharmaa stood at ₹3.98 Cr
The latest P/E ratio of MPS Pharmaa as of 20-Sep-2026 is 0.00.
The latest P/B ratio of MPS Pharmaa as of 20-Sep-2026 is -22.29.
The 52-week high of MPS Pharmaa is ₹2.08 and the 52-week low is ₹1.57.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of MPS Pharmaa is ₹0.00 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that MPS Pharmaa Ltd is a below average quality company.
The key valuation ratios of MPS Pharmaa Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of MPS Pharmaa Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About MPS Pharmaa Ltd
Advik Laboratories has been set up by V K Jain, a qualified production chemist with over 20 years experience in pharmaceutical products.
Advik Laboratories was established in the 1994. It is WHO-GMP certified company that has been set up from the ground level with the avowed objective of achieving USFDA standards of quality.
The company has a technical collaboration with PFC Pharma Focus of Switzerland. It enjoys leadership status at various fronts such as high product quality, a growing range of products, state of the art manufacturing process, competitive pricing and customer service. In addition the company exports a wide range of drugs to the Middle East, South America and Africa.
The product range includes ethical, generic drugs and over the counter drugs (OTC) in various formulations.
With over 60,000 square feet of built-up area, ample developed open space around it, a state-of-the-art manufacturing facility, the ground floor has provisions for the production and in-process control section for the manufacturing of steroidal & non-steroidal formulations, change room for gents & ladies and stores for raw & packing materials. The first floor has provision for the production and in-process control section for the manufacturing of ampicillin and non-ampicillin capsules and dry syrup preparations. The second floor has provision for quality control and about 12000 sq ft area is presently being reserved for the manufacture of injectables & ointments in the second phase.
Advik Laboratories provides pharmaceutical formulations that match the international standards of quality. The facility manufactures a wide range of pharmaceuticals formulations in tablets, capsules and dry syrups.
Products - Under Ethical products, the company manufactures Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin and Chewfe-C.
Under generic products, the company manufactures drugs catering segment such as antibacterials, antiallergics, antifungals, analgesic, antipyretic and anti-inflammatory, anti-hypertensives, anthelminthics, anti-malarials, corticosteroids, erectile dysfunction, gastrointestinal agents and sedatives.
Award - Advik Laboratories has received the prestigious Udyog Patra Award from the Government of India in 1999.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
